Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion
Retinal vein occlusion (RVO) is the most common visually disabling disease affecting the retina after diabetic retinopathy. Although the disease entity has long been known, its management is still controversial. Macular edema is the main reason for decreased visual acuity (VA) in this retinal vascul...
Main Author: | Marianne L. Shahsuvaryan |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2012-12-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530822/ |
Similar Items
-
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial
by: Ghader Motarjemizadeh, et al.
Published: (2017-08-01) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
by: Ivanovska Adjievska B, et al.
Published: (2017-06-01) -
Efficacy of intravitreal Conbercept injection for macular edema secondary to macular branch retinal vein occlusion
by: Ping-Li Zhu, et al.
Published: (2018-01-01) -
Report of intravitreal injection of Ranibizumab for macular edema caused by central retinal vein occlusion
by: Jing-Yi Lai, et al.
Published: (2016-04-01) -
Evaluation of early versus late intravitreal bevacizumab injection in the treatment of macular edema secondary to branch retinal vein occlusion
by: Hesham A Enany
Published: (2018-01-01)